Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do not hold your breath. First thing is the market must be assured Jack Perkowski is breathing.... really.
Next will be a display of mutual respect demonstrated by a gracious move by the Chinese government that there is an actual Plant Number5 (whatever #) that will produce X volume of parts for somewhere in some reasonable time frame.
If that happens within 3 months, I will be impressed. Sooner would indicate a Sino American relationship, which in part, had been formed some time ago (whoopie). Otherwise, I would not see the stock reach a dollar in less than a year. At that time the dollar would be reached overnight, like a rocket.
Buy now and you will see nothing for a while.... same old same old. If you time this one, you lose. So buy.
A bold statement indeed and what therefore are your preferences for the stock?
Ooops, Feb 26 after the close.
Please keep in mind the Chinese New Year will gum up the information transfer. 2014 Chinese year of the Horse. 2015 year of the Sheep. That sounds most ominous for investors. Pray for a good shepherd.
Q4 report should be around Feb. 24, 2015 but I am not sure. Anyone got the date/time?
IntRAday (within that one day) has hit momentarily below $5 but recovered well. I do not see it (without good factual reason) going under $5 intERday for a period of time. There have been a set of about 400,000 share shorts that have taken about 6 weeks to complete. Those have effected the $7 potential that was axed (nearly simultaneously) by the 12+million shares floated by CERS officers. Until the float gets fully bought and the additional shares cashed by the handlers (Cowan et al) I see a stall in the price. However, barring some other CERS officio making a doo-doo of the stock and the Q4 report at least neutral, there is a good reason to see the stock rise toward the $10 area of the spectrum. 2015 should be the year it all comes together. With plasma, platelets, red blood cells and whole red blood being deactivated of pathogens, acclaimed by the World Health Organization and garnering FDA kudos, the time is long past for a vertical upswing...... as I said, it will be like a rocket. There is no deadline for take off and anyone trying to time it is dead, when the short fuse is lit. Buy large and sit still.
Should be interesting to see if it is a dip or a plunge. Holding at $6 and later in the week a rise would be my expectation but that is up to the market forces. CERS certainly needs the marketing dollars if the product becomes a standard of care. Sales could be ok but fulfillment could be a catastrophe without the money to build the pipeline all over the world...... fast.
Most interesting was the 16th snapshot of George Coates standing with some Chinese execs next to a small portable gantry crane. In the far background, to the left (when magnified) is a serious telltale for me. The blue machine appears to be a numerical control lathe of large proportion. An enclosed lathe of this type would be required for the long and robust spherical turning and grinding of the rotary valve shafts. The size seems to affirm that such shafts would be for large diesel and otto cycle engines, Cat and other generator engines might utilize under the Coates patent. I feel that is but a censored snippet of what is actually on the floor. A lot of available production machinery is omitted but that one NC lathe says it all. Looks good to me.
I will reiterate my 4481 comment. At best, several weeks will pass before anything comes out. A guess would be January 9 or 12 of 2015 at the earliest (I really do not see it that early). Legal briefs and status filings must be made and checked first. Once the actual announcements are made, I believe the needle will move very little and slowly after weeks of interviews and publications confirm the action is real. Too many people have been losers on this stock (their choice though) for it to move quickly. I may lose also but it sure is fun to await the outcome.
Nope. As is typical, many took their profits and ran for the door. That is cool by me.
I would expect $30-$40 by April 2015, $70 by August and $100 by the end of 2015. All this is my personal speculation, not withstanding that my $80 price might be a corporate offer of $40 cash and a stock certificate value of about $40. Who knows? I felt it should have been well over $10 nearly three years ago but CERS just had to issue stock at $2.85 a share to amass a lump of phase 2 money and blew the stock off of its $5 value and derailed the trend toward the $10 mark. The move was correct but it shot the heck out of the forward inertia. It is certainly worth the hold and patience.
As much as I like the product (invention) and have a significant position, I have serious doubt that anything at all will be published by George and Gregory until nearly a week after New Years day. Why? All of the lawyers are on Christmas break as are the major chunks of the USA government that might have some oversight on foreign trade, investment and banking. Add to that mix that the Chinese New Year is on February 19, 2015 and has an unreal lead up to that date. I am certainly not holding my breath..... as I have said in the past, the dealings with Chinese business is really dealing with an overburdened and lethargic government. All considered, I will hold on and do what is politically correct in China..... wait.
USA red blood cells at successful phase 2 and Europe the red blood cells at phase 3 and going for CE.
I bought 4/21/09 a $1.08..... have stayed long and will sell at over $100. Yep, you heard correctly.
12/22/2014 08:31:06 AM EST
Cerus Corporation (NASDAQ: CERS) announced today that its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated red blood cells continued to circulate 24 hours following transfusion. The investigators plan to submit data from the study for presentation at an upcoming scientific congress.
"We are pleased with the results of this study, which support the future advancement of the INTERCEPT red blood cell program into a Phase 3 study in the United States," said Dr. Laurence Corash, Cerus' Chief Medical Officer. "The data from this study met recommended criteria for a successful red cell recovery study and demonstrate that INTERCEPT red cells behave similarly to untreated red cells when infused into healthy volunteers.?
The randomized, single-blind, controlled, multi-center Phase 2 clinical trial of the INTERCEPT red blood cell system evaluated 26 healthy subjects at two United States clinical trial sites. Each subject received two transfusions of the subject's own red blood cells, one INTERCEPT-treated, and the other a control not treated for pathogen inactivation. Red blood cell units were stored for 35 days prior to transfusion. The primary endpoint of the clinical trial, a mean INTERCEPT red blood cell recovery of greater than 75 percent at 24 hours post-transfusion, was met. The INTERCEPT red blood cells had a recovery of 83% compared to 85% for control red blood cells, and both INTERCEPT-treated and control red blood cells met the criteria for red blood cell recovery recommended by the U.S. Food and Drug Administration.
In Europe, Cerus recently completed a Phase 3 clinical study of the INTERCEPT red blood cell system in patients with acute anemia and plans to file for CE mark approval.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
I await the new information about the deal and future financial opportunities with abated breath.
One million shares for $10,000. HHMMmmmm.... Later next year, some people may be very angry at themselves for not making that purchase today. Half a million shares would even be nice. Ah, the damed decisions, especially for those that had lost tens of thousands of dollars over 10 years. Might this be the time for just one $5k parting shot? If one lost $50K, what is just another $5k ? The return could be enormous.... IF.....
And for good reason.... This is RED Blood cells not just the Plasma and Platelets.
12/09/2014 07:04:31 AM EST
By Targeted News Service
ALEXANDRIA, Va., Dec. 9 -- Cerus, Concord, California, has been assigned a patent (8,900,805) developed by Naheed Mufti, San Ramon, California, Anna Erickson, Richmond, California, and Anne North, Pleasant Hill, California, for the "quenching methods for red blood cell pathogen inactivation."
The patent application was filed on April 9, 2009 (12/936,763). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=89,00,805.PN.&OS=PN/89,00,805&RS=PN/89,00,805
Written by Balkishan Dalai; edited by Jaya Anand.
BD1209JA1209-1088772
Thank you doughflow. Any USA citizen could make a crackpot Chinese-like web site, put gobbledegook words on it and pass it out as real.... no arrests would be made. Try that in China or as a visitor to China and the entanglements one would reap are nothing less than ferocious. George definitely seems to have their ear and the potential of their wallet. The folks in China that are running their side of this deal are no less smart than any in this forum.... that is a gross understatement. They are well educated and superbly business savvy. Those of this forum, such as I, who may have lost money, I sympathize with you. I do not believe this is a farce. I am concerned that COTE investors who currently have money in the company could get put aside somehow and I shall be watchful of that. Otherwise I am all in.
BINGO!!!! You nailed it. I bought at $4 and sold at $9 (after zooming down from ~$13). I will not (as said before) buy this stock again until it slides into $4. It is a great technology but the marketing folks are out of sync with the reality. I have no short position, as it is too sketchy for me. I am just out for now. Hope you all make some money on ONVO.
Answer: 1. engine manufactures have huge investments in valve types, materials, engineers and tooling. 2. there is no competition to change the use of poppet valves. 3. only a nation bent on totally disrupting and taking over engine development during the remaining of the 'fossil fuel' century could take such a threatening step to current engine design. 4. the $100,000,000 dollars is minuscule compared to how the base engines stay the same except for the cylinder head (super profits). 5. the Canada thing was the sale of a bunch of engines, far different from arming a half billion person country with a massive impact to change engines all over the world in one swipe..... and the financial clout to boot it out of the park. 6. the license is non exclusive and actually will put the Chinese in control of technology adoption globally (you will have to really think on that one). 7. not a single car company, but a whole nation will change all of internal combustion engines, pollution, economy and application criteria. Detroit and Europe did not listen to the man... they will adopt it later while still trying to perfect the electric vehicles. 8. fossil fuel is not going away very soon and the Chinese are going to clean out engine manufactures wallets at the same time they give them a way to put the new heads on old engine designs. 9. the new heads will be options for a higher margin for car manufactures, at less production cost with greater profit. That refills the wallets, forces federal mandates and make the Chinese more wealthy.
I agree with BOR1. I have seen this story before with China. In America, such protracted business dealings are at best frowned upon and at worst see a CEO marching out the door. However this is dealing with China, with which I have more than a passing acquaintance. So far, everything is by the book.... the Chinese book and I feel very confident a real business deal with significant financial reward for COTE investors is on the way. The key element is the acceptance in whole of the Coates patented machinery or a level of unacceptability that would create an alternate contract. The engine on the ground is an important milestone. I look forward to hearing the test outcome in a few months.
Bill Gates? The Africa study will take an added step — use of an experimental system by Cerus Corp. for inactivating viruses in blood.
Dr. Ada Igonoh, a doctor in Nigeria who got Ebola from a patient and recovered, expects to donate plasma and recruit others for the study.
"Survivors will be willing if they understand the goal," she said.
She and Brantly met with Gates to discuss the project earlier this month at an American Society of Tropical Medicine & Hygiene conference in New Orleans.
excerpted from..... http://www.cnbc.com/id/102197664
Whoops! Looks as if another 2 quarters will pass by before CERS gets a reprieve from the down side. A future languishing in the $3.80 to $4.00 zone...... if the Greenman does not offer another discounted round of self inflicted financing (floating more stock). I am long too. This stock will be more like a Tourette Syndrome (no malice meant to those afflicted). The longer this stock languishes the more vertical the climb to its future highs. It is definitely proving NOT an overnight success. I could not ask for a better type of investment... the wait will be worth the time. However, this is a painful vigil.
You are a very wise person. The 1,189,000 shares sold today represent only $24,000. If someone is on a lark with $25k into a purchase of COTE stock tomorrow, that individual stands to make a large fortune if the stock rises back toward $1.
I feel a buy was in for this stock about a year or more ago, by the Chinese as a sell event of todays timing. A small amount is sacrificed to set the buy later (when I do not know). The idea is to chase the current holders out and rattle nerves of the discontented.
This is so very interesting. If Coates is BSing, that is bad but could be expected. If the deal is real.... WOW to the holders on.
I referred to PCYC and would not be a buyer of that stock right now. However, I do not see that stock worth 7 billion, 5 billion or even 2 billion either. In feb 2009 it closed at 57 cents. I would say CERS has more to offer the world. Maybe you could tell me how it got to $134+, huh?
Kid,Texas, Mynuttoo, and others who feel their investment has been swamped by the Coates group, you all have my sympathy...... not my empathy. I do not invest founding shares in companies that have profit/loss sheets of which to be proud, established through hard work and long times slogging through the markets in which they compete. INVENTION is decidedly different, as is pure research (not development). A 'Popular Science' and other tech articles often pull in investors with a business savvy. The problem is that an inventor/entrepreneur individual is an atypical business model. The problems encountered are vastly different from a storefront business model. Such people live in a world that is closer to savants than to engineers, financial experts, programmers and retailers. It is by virtue of NOT adhering to sound and accepted principals that nets them the invention(s) in the first place. When they approach a typical market structure in which to 'sell' their idea, the market is nearly incomprehensible to the inventor/entrepreneur. The I/E must shift gears and become that which he never was... a wily, practiced business man, maybe like you.
To add to the I/E's misery, are the myriad dead ends through which he must learn, frittering away time and money to the enmity of his investors. You folks have done well in business and I applaud you and the powerful strides you have made. Please recognize that the I/E is beyond most people's and especially investor's culture. There is just no measure for George Coates, whom I admire and in whom I invest. I particularly look for and do find such rarities on occasion, to add to the more mundane and consistent equities currently held. Their success is a pleasure beyond financial rewards but I like the rewards too.
It is about time something positive happens. I hold private equity in several companies that have specific need for the Chinese to be doing the manufacturing. One company has had direct Chinese business contacts and contracts for well over thirty years and getting their patents into manufacturing slots still takes the 'full national government' involvement..... right down to the government ASSigning what specific company or companies will be involved. If you think the US government is intrusive, you haven't seen anything. Coates has in fact, moved very swiftly to this point. My fear is that he may have given too much away to the Chinese but time will tell. Most investors have no idea of the timelines and frustrations involved. If you do not like George Coates, his family, your loss of your money or any other dislike you may harbor, remember the idea of due diligence and personal responsibility. I may lose it all on Coates but that can never change the respect I have for his dogged determination to get his idea into an engine market that deplores his invention and industriousness. I am long term with this stock whether it 'does or dies'. If you do not like that idea, get a life or buy some COTE stock again.
CERS seems to appear to day traders, as an instrument with which to make money quickly in a six hour period. A few make money, the rest pay the few's profits (typical). Either one tries to make money in the brief period or long term on CERS. For the most part, the stock is a no brainer and will be played at 3 to 4 dollars until the 'news dam' bursts. Park a large chunk of money in CERS and watch it do a PCYC.... but in a much shorter time frame. Time frame for this is up for grabs. I feel it happens in the next year (my best guess). This is an over a hundred dollar stock, period.
For this retiree, a 12+% return on a now monthly basis with more frequent NAVs...... it sure does smooth out the prior nasty bumps in the road. And as Neb said "anything under $26 is a buy". However, $31 per share would be nice Q1 of 2015.
SEC Reg effective...Just another little nut to crack.....
Date: Wednesday, September 17, 2014
Ticker: OTC:BB:COTE
WALL TOWNSHIP, NJ / ACCESSWIRE / September 17, 2014 / Coates International, Ltd. ("the Company") (OTCQB: COTE) (the "Company"), is pleased to announce that its Registration Statement filed with the Securities and Exchange Commission ("SEC") has been declared effective. The Company can now commence utilizing the equity line of credit with Southridge Partners II LP ("Southridge") which can provide the Company with up to $10 million in working capital from the sale of up to 40 million registered shares of its common stock. Pursuant to the underlying Equity Purchase Agreement, Southridge is committed to purchase up to $10,000,000 of the Company's stock over the course of 36 months. Details of the agreement can be found in the Company's registration statement filed with the SEC on August 29, 2014. George J. Coates, President & CEO, stated, "the funds will be accessed at our sole option, which shall be based on the consideration by our management of various business and economic conditions, with the objective of endeavoring to strike a balance between achieving our business plan." There can be no assurance that the Company will be able to utilize the entire equity line of credit facility. Safe Harbor Statement: This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see our filings with the Securities and Exchange Commission. Our public filings with the SEC may be viewed and printed on the website maintained by the SEC at http://www.sec.gov. CONTACT: Coates International, Ltd. Phone: 732-449-7717 Fax: 732-449-0764 SOURCE: Coates International, Ltd.
You nailed it! Coates has been at this for decades. I also agree that it looks really bad. That considered, I still keep my big chunk of stock bought for much less than one thin dime a share and will probably keep it for decades to come.... with many prayers, at least a buck a share. It is the one long shot I own based on actual sight and touch of the object of its creator. For me it is fun and more than an investment.
You are indeed correct.... Far better for one to remain silent and look stupid than to speak and remove all doubt.
IKOP..... I AM arguing whether or not the data (not cited) is fact. Where can I see the data you say is inarguably factual?
With all due respect Ikop, where is the data that describes this increase in activity. Please substantiate. Thank you.
I was wrong... thought it might dip to 4 or 5 $ per share in July. PR is excellent for ONVO, keeping investors and media informed.
A superb 'well done' to you. The most reassuring part, to me, is that the whole area in which the two companies are involved may have made the whole world suddenly take note of the techno-pharma horizon. Talk about a great leap! Thank you for your diligence drkazmd65.
drkazmd65... With all due respect to your knowledge and background, I believe the date and context of this older report attached, does indeed progress historically to last weeks timely use of the zMapp drug. My question is, who or what company is responsible for the zMapp serum? What is that company's track record and what are the US Governments financial relationships with such company? Ebola and HIV/HPV are different but very deadly viruses.
The last line of the second paragraph is a zinger. Not to mention investor glee for last line of third paragraph.
Re: Cel-Sci corporation CVM
Berichtdoor rood&wit » 07 Feb 2014 15:33
Navy CRADA Fast-Tracks Cel-Sci's Immunotherapy For HPV
With recent news of an upcoming clinical trial, CEL-SCI Corporation (CVM) proves to be one of the best bets on the fast track of immunotherapy, drugs using the body's own natural defenses to fight disease. Its latest win is approval from the US Navy to begin a dose escalation Phase I study using Multikine, the company's proprietary version of small proteins that regulate immune response and inflammation, in men and women suffering from both HIV and human papilloma virus (HPV) that have developed unsightly and potentially dangerous warts around the anus. HPV is particularly insidious because of the lack of overt symptomology, making it the commonest of sexually-transmitted diseases.
Just last fall, CEL-SCI signed a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Center in San Diego, CA, a center of excellence in HIV and AIDS care with more than 30 clinical trials done to date, for a human study pursuant to approval from the Navy's Institutional Review Board (IRB) consisting of a body of experts that sanction clinical trials. This has been achieved, allowing immediate patient enrollment. Along with peri-anal warts, Multikine's effect on anal intraepithelial dysplasia, a forerunner to anal cancer, will be measured. The study will not take long with results expected this year.
Initial patients will be treated and observed for six weeks; if side effects are not severe, additional subjects will be added at a higher dose. CEL-SCI plans to leverage the clinical trial design of a Phase I study done at the University of Maryland in cervical dysplasia in those co-infected with HIV and HPV, where administration of Multikine resulted in lesion reduction and the elimination of some HPV strains, of which up to150 exist with varying degrees of cancer potential. Importantly, CEL-SCI is not required to relinquish patent rights, does not owe money to the Navy and stands to exclusively license any new technology, if developed.
May well be a concerted push downward by larger investment groups in order to position themselves for a lower entrance investment cost. There may also be some lingering doubt before the Thursday evening 2nd quarter results. Either way, if the numbers are good this time, CERS should begin to rise again. I feel there are a lot of big investment groups ready to pounce.... it is inevitable but when and under what specific condition is a craps shoot. Long, in this case is very good. Could be two days or two years. Keep hang'n in there.
Looks as if folks are buying now though. With the 'taper' dissolving, is there anyone that feels an increase in AGNC from 11 to 15% and a stock price around $30 is in the 1-2 year future?
What in particular has gotten your concern about the S filing?
Maybe this is the hold up.... Another patent update for CSRV on a radial swash-plate engine.
Will the "jargon" never end? I will wait too but I do not want to end up as Rip Van Winkle.
07/17/2014 12:42:18 PM EDT
By a News Reporter-Staff News Editor at Politics & Government Week -- From Washington, D.C., VerticalNews journalists report that a patent application by the inventor Robards, Brian (Camas, WA), filed on January 1, 2013, was made available online on July 10, 2014.
No assignee for this patent application has been made.
News editors obtained the following quote from the background information supplied by the inventors: "Prior Art
"The following is a tabulation of some prior art that presently appears relevant:
"TABLE-US-00001 US Patents Pat. No. Issue Date Patentee 6,202,606 2001-03-20 Anttila 2010/0180868 2010-07-22 Scalzo 4,944,261 1990-07-31 Coates
"This relates to internal combustion engines, specifically four stroke internal combustion engines which utilize an axial piston arrangement. Four stroke internal combustion engines tend to not use all of the thermal energy of the fuel that they burn to produce power, if the engines were to be designed in a way which would improve the thermal efficiency the power produced would increase and the fuel consumption would decrease. The issues with most four stroke internal combustion engines is that during the power stroke the piston expansion ratio is limited by the engine architecture, this results in the pressure resulted from the energy of the burned fuel not being able to produce the optimum amount of power. In these engines when the piston has reached its lowest point in the power stroke the exhaust valve is opened and the excess cylinder pressure escapes from the engine as engine exhaust. Engine manufacturers have experimented with various means of engine design which could act to make more efficient use of the fuels energy.
"U.S. Pat. No. 6,202,606 to Anttila (2001) shows an axial piston engine. This engine uses a thrust yoke arrangement and six pistons arranged radially around a central output shaft. This engine is designed such that the pistons and the output shaft are arranged parallel to each other. This engine design was such that the lengths of the intake/compression and expansion/exhaust strokes were the same so it did not benefit from the thermodynamic advantages of overexpansion.
"U.S. Pat. No. 2010/0180868 to Scalzo (2010) shows an engine design that uses a rocker mechanism to actuate vertical movement of a piston in the engine's cylinder. The rocker mechanism is uses such that it produces an intake/compression stroke that is shorter than the expansion/exhaust stoke allowing this engine design to have an increased thermal efficiency due the overexpansion present. The rocker mechanism that is used to actuate the piston movement is rather complex and would add a significant amount of cost to the production of the engine.
"U.S. Pat. No. 4,944,261 to Coates (1990) show a rotary valve assembly used in internal combustion engines to actuate the air intake and exhaust events of the engine. This design uses a rotary valve mounted on a shaft which have ports in the rotary valve, which when rotated allow air to enter and exit the combustion chamber of the engine through these ports. By using these rotary valves instead of the standard valvetrain components (poppet valve, valve springs, rocker arms, pushrods, etc) the engine will experience less frictional losses. The typical valvetrain components are also known to have natural frequency issues that limit the speed at which they can operate, the use of the rotary valves will eliminate these natural frequency issues and allow the engine to operate at higher engine speeds."
As a supplement to the background information on this patent application, VerticalNews correspondents also obtained the inventor's summary information for this patent application: "An improved four stoke internal combustion engine is designed such that the distance that the piston travels during the intake/compression stroke are much less than the distance travelled during the expansion/exhaust stroke. Each cylinder of the engine has the piston movement activated by a barrel that is split into two halves, which have channel in the shape of a sinusoidal wave. The circular ends of the connecting rods can slide through this sinusoidal shaped wave in the barrel. As the barrel rotates the connecting rod is forced to move vertically by this channel, and the channel is designed such that the shape is mirrored about the center point so that both ends of the connecting rod always have the same vertical position. The channel in the barrel is shaped such that the sinusoidal wave associated with the intake/compression strokes have smaller amplitude than the sinusoidal wave associated with the expansion/exhaust strokes.
"The improved engine has five cylinders which are arranged radially around a center main shaft. Each cylinder barrel has a timing gear attached to it which spins to rotate a main timing gear. As the main timing gear rotates it is attached to a main shaft which acts to rotate a main slide valve gear in between the upper and lower cylinder head. Each cylinder of the engine has a slide valve which is mounted between the upper and lower cylinder heads that are driven off of the main slide valve gear. As the slide valves rotate they have ports in them which are used to allow air into the engine through the intake ports and allow exhaust to escape from the engine through the exhaust ports. A typical engine uses poppet valves which are activated by a camshaft and various lifters/pushrods/cam followers/etc, these parts act to increase the friction in the engine and reduce the overall engine efficiency. The use of the slide valve should act to reduce the overall engine friction and improve efficiency."
For additional information on this patent application, see: Robards, Brian. Axial Piston Internal Combustion Engine Using an Atkinson Cycle. Filed January 1, 2013 and posted July 10, 2014. Patent URL: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=7396&p=148&f=G&l=50&d=PG01&S1=20140703.PD.&OS=PD/20140703&RS=PD/20140703
Keywords for this news article include: Patents, Legal Issues.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC